In vitro triple culture model of retinoblastoma for pre-clinical investigations

BackgroundRetinoblastoma (Rb) is a rare cancer of the retina that occurs during early childhood. The disease is relatively rare but aggressive, accounting for similar to 3% of childhood cancers. Treatment modalities encompass the administration of large doses of chemotherapeutic drugs, which result in multiple side-effects. Therefore, it is essential to have safe and effective newer therapies and suitable physiologically relevant, alternative-to-animal, in vitro cell culture-based models to enable rapid and efficient evaluation of potential therapies. MethodologyThis investigation was focused on the development of a triple co-culture model comprising Rb, retinal epithelium, and choroid endothelial cells, using a protein coating cocktail, to recapitulate this ocular cancer under in vitro conditions. This resulting model was used for screening drug toxicity, based on the growth profile of Rb cells, using carboplatin as the model drug. Further, a combination of bevacizumab and carboplatin was evaluated using the developed model, to lower the concentration of carboplatin and thereby reduce its physiological side-effects. Major ResultsThe effect of drug treatment on the triple co-culture was assessed by increase in the apoptotic profile of Rb cells. Further, the barrier properties were found to be lower with a decrease in the angiogenetic signals that included expression of vimentin. Measurement of cytokine levels signified reduced inflammatory signals due to the combinatorial drug treatment. ConclusionsThese findings validated that the triple co-culture Rb model was suitable for evaluating anti-Rb therapeutics and could thereby decrease the immense load on animal trials, which are the primary screens employed for evaluating retinal therapies.

Automated summary

This study developed a triple co-culture model consisting of retinoblastoma, retinal epithelium, and choroid endothelial cells, using a protein coating cocktail, to replicate this ocular cancer under in vitro conditions. The model was used to screen drug toxicity based on the growth profile of retinoblastoma cells, using carboplatin as the model drug. Furthermore, a combination of bevacizumab and carboplatin was evaluated using the developed model to reduce the concentration of carboplatin and its physiological side-effects.